Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Ambati · SciRah

Researcher profile · Semantic Scholar

S. Ambati

Share profile

S. Ambati — researcher profile on SciRah

h-index: 18
Works: 127
Citations: 2,481

Most-cited papers

Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
A. Hoshino, Han Sang Kim, L. Bojmar, K. Gyan +113 more
2020Cell1,118 citations Open access
Semantic Scholar
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
R. Bannerji, J. Arnason, R. Advani, Jennifer R. Brown +15 more
2022The Lancet Haematology187 citations Open access
Semantic Scholar
Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy
R. Bannerji, J. Allan, J. Arnason, Jennifer R. Brown +15 more
2020102 citations Open access
Semantic Scholar
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.
T. Kim, M. Taszner, S. Novelli, S.-G. Cho +27 more
2024Annals of Oncology83 citations Open access
Semantic Scholar
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
W. Kim, Tae Min Kim, Seok-Goo Cho, I. Jarque +126 more
2025Nature Cancer60 citations Open access
Semantic Scholar
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
R. Bannerji, J. Allan, J. Arnason, Jennifer R. Brown +30 more
2019Blood57 citations
Semantic Scholar
Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
S. Ayyappan, W. Kim, Tae Min Kim, J. Walewski +21 more
2023Blood48 citations Open access
Semantic Scholar
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Max S. Topp, M. Matasar, J. Allan, S. Ansell +15 more
2024Blood33 citations Open access
Semantic Scholar
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Jurriaan Brouwer-Visser, N. Fiaschi, R. Deering, K. Cygan +15 more
2024Journal for ImmunoTherapy of Cancer28 citations Open access
Semantic Scholar
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
W. Kim, Tae Min Kim, Seok-Goo Cho, I. Jarque +16 more
2022Blood27 citations Open access
Semantic Scholar
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.
Ashish O. Gupta, Akshay Sharma, H. Frangoul, Julie Kanter +22 more
2026New England Journal of Medicine19 citations
Semantic Scholar
Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions
S. Ambati, E. Slotkin, E. Chow-Maneval, E. Basu
2018JCO Precision Oncology17 citations Open access
Semantic Scholar
Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes
R. Bannerji, J. Arnason, R. Advani, Jennifer R. Brown +22 more
2018Blood17 citations
Semantic Scholar
Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Tae Min Kim, M. Taszner, Seok-Goo Cho, S. Novelli +17 more
2022Blood16 citations
Semantic Scholar
Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance
Jurriaan Brouwer-Visser, N. Fiaschi, R. Deering, A. Dhanik +19 more
202015 citations
Semantic Scholar
Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma
J. Jalbert, N. Wu, Chieh-I Chen, S. Ambati +2 more
2022Advances in Therapy14 citations Open access
Semantic Scholar
Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up
J. Villasboas, Tae Min Kim, M. Taszner, S. Novelli +26 more
2023Blood13 citations Open access
Semantic Scholar
Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies
Min Zhu, Kara Olson, J. Kirshner, Masood Khaksar Toroghi +9 more
2022Clinical and Translational Science13 citations Open access
Semantic Scholar
Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).
M. Matasar, B. Turgut, B. Tessoulin, S. Guidez +14 more
2024Journal of Clinical Oncology11 citations
Semantic Scholar
A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
T. Kim, A. Alonso, M. Prince, M. Taszner +19 more
202011 citations Open access
Semantic Scholar
Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study
Tae Min Kim, Seok-Goo Cho, M. Taszner, G. Chong +6 more
2024Blood10 citations
Semantic Scholar
Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study
J. Crombie, M. Matasar, M. Topp, J. Allan +15 more
2023Blood9 citations
Semantic Scholar
Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
Umberto Vitolo, M. Merli, L. Norasetthada, Tim Wassenaar +11 more
2024Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
J. Allan, J. Crombie, M. Matasar, Max S. Topp +10 more
2024Blood8 citations
Semantic Scholar
Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).
C. Hardin, C. Gray, S. Novelli, T. Hacıbekiroğlu +13 more
2024Journal of Clinical Oncology8 citations
Semantic Scholar
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2
S. Novelli, S. Luminari, M. Taszner, S. Cho +17 more
2023Hematological Oncology8 citations Open access
Semantic Scholar
Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL
Jon E. Arnason, M. Matasar, S. Luminari, D. Tucker +11 more
2025Blood Advances7 citations
Semantic Scholar
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2
M. Poon, J. Walewski, T. Kim, S. Cho +16 more
2023Hematological Oncology7 citations Open access
Semantic Scholar
Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).
R. Birhiray, S. Luminari, Tae Min Kim, M. Yağcı +12 more
2024Journal of Clinical Oncology6 citations
Semantic Scholar
Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies
Min Zhu, Daniela J Conrado, K. Srinivasan, Jurriaan Brouwer-Visser +6 more
2023Blood6 citations Open access
Semantic Scholar
Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study
Elizabeth A. Brem, W. Jurczak, D. Belada, Jaime Pérez de Oteyza +15 more
2024Blood5 citations
Semantic Scholar
PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
B. Tessoulin, S. Guidez, Manjusha Namuduri, Ashish Risal +10 more
2023HemaSphere5 citations Open access
Semantic Scholar
Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
M. Weinstock, P. Elavalakanar, S. Bright, S. Ambati +9 more
2022British Journal of Haematology5 citations Open access
Semantic Scholar
Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study
Ashish O. Gupta, Akshay Sharma, H. Frangoul, Julie Kanter +21 more
2025Blood4 citations
Semantic Scholar
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study.
B. Tessoulin, J. Harnett, Seok-Goo Cho, M. Taszner +28 more
2025Clinical Lymphoma, Myeloma & Leukemia4 citations Open access
Semantic Scholar
P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
J. Walewski, Tae Min Kim, Seok-Goo Cho, I. Jarque +16 more
2023HemaSphere4 citations Open access
Semantic Scholar
Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
E. Iskierka-Jażdżewska, W. Kim, Seok-Goo Cho, Tae Min Kim +23 more
2023Blood4 citations Open access
Semantic Scholar
PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
U. Vitolo, E. Phillips, A. Alonso, M. Merli +11 more
2023HemaSphere4 citations Open access
Semantic Scholar
A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
M. Topp, J. Duell, Jing-Jin Li, V. Janković +6 more
2019Blood4 citations Open access
Semantic Scholar
CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)
Max S. Topp, J. Arnason, R. Advani, Jennifer R. Brown +23 more
2019Hematological Oncology4 citations
Semantic Scholar
The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the treatment of Ewing sarcoma (ES).
P. Meyers, S. Ambati, E. Slotkin, F. D. Cruz +1 more
20184 citations
Semantic Scholar
Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review
B. von Tresckow, P. Abrisqueta, I. Zamanillo, Á. Serna +16 more
2025European Journal of Haematology3 citations Open access
Semantic Scholar
Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4).
Eliza A. Hawkes, Tae Min Kim, E. M. Donato Martín, Amanda Núñez-García +12 more
2024Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab
G. von Keudell, Eliza A. Hawkes, C. Carpio, Max S. Topp +8 more
2024Blood3 citations
Semantic Scholar
P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
M. Taszner, S. Luminari, Seok-Goo Cho, S. Novelli +17 more
2023HemaSphere3 citations Open access
Semantic Scholar
Circulating Tumor DNA Analysis Associates with Progression-Free Survival (PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM
J. Arnason, Jurriaan Brouwer-Visser, S. Luminari, D. Tucker +10 more
2023Blood3 citations Open access
Semantic Scholar
Modeling and Simulation in Support of Odronextamab Subcutaneous Dose Selection for Adult Patients with Indolent or Aggressive Non-Hodgkin Lymphoma
Min Zhu, S. Ambati, H. Mohamed, Masood Khaksar Toroghi +3 more
2022Blood3 citations Open access
Semantic Scholar
Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical review
P. Abrisqueta, A. Jiménez-Ubieto, Á. Serna, I. Zamanillo +16 more
2025Annals of Hematology2 citations
Semantic Scholar
Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
W. Kim, Tae Min Kim, Seok-Goo Cho, I. Jarque +126 more
2025Nature Cancer2 citations Open access
Semantic Scholar
Enhanced CD34+ cell mobilizations, collections, and comparable safety profile with fixed-dose versus weight-based plerixafor dosing in patients with sickle cell disease receiving autologous CD34+ base-edited hematopoietic stem cells (BEAM-101) in the ongoing BEACON study
H. Frangoul, B. Habtemariam, Arthur Lo, S. Ambati +6 more
2025Blood2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Chaudhry×34
Invite
A. Chaudhry — researcher profile on SciRah
H. Mohamed×30
Invite
H. Mohamed — researcher profile on SciRah
Jurriaan Brouwer-Visser×18
Invite
Jurriaan Brouwer-Visser — researcher profile on SciRah
Min Zhu×16
Invite
Min Zhu — researcher profile on SciRah

×11

Invite

M. Ufkin — researcher profile on SciRah

E. Iskierka-Jażdżewska×11

Invite

E. Iskierka-Jażdżewska — researcher profile on SciRah

Invite

J. Arnason — researcher profile on SciRah

Invite

J. Duell — researcher profile on SciRah

Invite

M. Taszner — researcher profile on SciRah

Invite

J. Allan — researcher profile on SciRah

Invite

Jing-Jin Li — researcher profile on SciRah

Invite

Tae Min Kim — researcher profile on SciRah